Particle.news

Download on the App Store

AstraZeneca Reports Q1 Growth and Expands US Investments Amid Regulatory Challenges

The pharmaceutical giant posts 10% revenue growth, accelerates US manufacturing and R&D plans, and faces legal scrutiny in China over tax and data issues.

Overview

  • AstraZeneca reported a 10% increase in Q1 2025 revenue to $13.6 billion, driven by strong performance in oncology and biopharmaceuticals.
  • The company reaffirmed its $80 billion annual revenue target by 2030, citing progress in its drug pipeline and global growth strategy.
  • Amid a US national security investigation into pharmaceutical imports, AstraZeneca announced expanded investments in US manufacturing and R&D facilities in Maryland and Massachusetts.
  • In China, the company is under investigation for $1.6 million in alleged unpaid import taxes and potential data infringement, which could result in significant fines.
  • AstraZeneca continues to navigate fallout from the arrest of its former China president and employee convictions for insurance fraud tied to its cancer drug Tagrisso.